Sales in the global Radiation-Induced Myelosuppression Treatment Market are slated to total USD 2.9 Billion in 2022. Expanding at a steady 3.1% CAGR, the market valuation is projected to top USD 3.5 Billion in 2028.
| Attribute | Details |
|---|---|
| Radiation-Induced Myelosuppression Treatment Estimated Market Size 2022 | USD 2.9 Billion |
| Radiation-Induced Myelosuppression Treatment Market Value-based CAGR (2022 to 2028) | 3.1% |
| Radiation-Induced Myelosuppression Treatment Market Projected Size in 2028 | USD 3.5 Billion |
Increasing incidence of cancer worldwide is underpinning the need for advanced cancer treatment options and therapies. Early diagnosis and the availability of radiotherapy and chemotherapy are expected to fuel sales in the market through 2031.
In addition to this, the introduction of adjuvant therapy for cancer is playing a vital role in reducing the death rate of cancer, improving disease management, and the overall quality of life in cancer patients. As per Future Market Insights, the market is projected to expand on the back of the aforementioned factors over the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 3.42% |
| H1, 2022 Projected | 3.12% |
| H1, 2022 Outlook | 2.62% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 50 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 80 ↓ |
Future Market Insights presents a comparative analysis about the market growth rates and development prospects in the global market. According to FMI analysis, the radiation-induced myelosuppression treatment market is expected to drop by 80 Basis Point Share (BPS) in H1- 2022 compared to H1-2021.
However, BPS change of only 50 BPS was observed when comparing H1-2022 Outlook and H1-2022 Projected growth. Key reason for this dip in BPS is attributed to the factor such as stringent government regulations and approval process for pipeline products, which impacted the growth of the market.
However, some positive factors which will influence the market growth in future include new developments and introduction of novel therapeutics for treatment of radiation induced myelosuppression. For instance, on Feb 2021, FDA approved trilaciclib (Cosela, G1 Therapeutics) for lowering the rate of chemotherapy-induced myelosuppression (CIM) in adult patients suffering from extensive-stage small-cell lung cancer (ES-SCLC).
Demand in the radiation-induced myelosuppression treatment market is projected to increase at a 3.1% CAGR, in comparison to the 3.4% CAGR registered between 2013 to 2031.
The availability of various growth factors and favorable treatment guidelines have made the management of neutropenia easier. However, thrombocytopenia and anemia are still posing a burden on the healthcare system.
Thrombocytopenia can be managed with the help of available growth factors, but most of them are off-label. The management of anemia remains a challenge for cancer patients who receive radiation therapy for cancer treatment.
Due to changes in reimbursement and labeling of medications for anemia, the use of off-label indication erythropoietin-stimulating agents has decreased to an extent. This has resulted in growing need for blood transfusion, which is associated with various risk factors.
This, in turn, is underscoring the significance of myelosuppression treatment therapeutics and drugs, which is expected to boost the market over the assessment period.
Principal Consultant
Anemia is a common consequence of chronic kidney diseases (CKD) and radiation-induced myelosuppression. Due to the insufficiency of erythropoietin synthesis, patients suffer from anemia. However, the combination of erythropoiesis-stimulating agents (ESA) and iron has become a standard treatment for anemia.
ESAs effectively increase the hemoglobin (Hb) levels in patients. However, their use has been associated with increased cardiovascular risk, especially due to high dose intake in inflamed and hyporesponsive patients.
Iron deficiency is another consequence of anemia. This has resulted in the introduction of intravenous iron therapy which is beneficial for anemic patients, CKD patients, and patients dealing with heart failure.
A new class of drugs, namely prolyl hydroxylase domain (PHD) inhibitors is now available for the treatment of anemia. These drugs effectively stimulate the synthesis of endogenous erythropoietin and increase iron availability.
In addition to this, in February, the USA Food and Drug Administration (FDA)approved Cosela (Trilaciclib) as the first line of treatment in its class to reduce the frequency of bone marrow suppression in adults, which is caused by chemotherapy for the extensive stage.
Such developments are expected to provide impetus to the growth of the market over the assessment period, opines FMI.
High Prevalence of Chemotherapy Induced Myelosuppression Will Spur Demand in the USA
The USA is expected to dominate the North America radiation-induced myelosuppression treatment market owing to growing incidence of cancer, chronic kidney diseases (CKD), and patients dealing with heart failure.
The presence of leading market players and fast-tracked approvals by the FDA are expected to augment the growth of the USA market. In addition to this, the USA is home to a vast healthcare sector, which is expected to provide opportunities for growth to market players over the assessment period.
Healthcare Providers are Prescribing Myelosuppressive Chemotherapy Drugs To improve Bone Marrow Function
China is expected to account for a lion’s share of the East Asia radiation-induced myelosuppression treatment market. Increasing geriatric population in the country, along with high incidence of cancer and heart failure are spurring the demand for myelosuppression treatment drugs.
Further, increasing research and development activities for the development of iron deficiency treatment is expected to augment the growth of the market. Iron deficiency is a consequence of anemia caused by chemotherapy radiation.
Growing preference for erythropoiesis-stimulating agents (ESAs) for iron deficiency in the country is anticipated to boost the market in the forthcoming years.
Surging Trend of Medical Tourism Will Boost Sales of Myelosuppression Chemotherapy Drugs
The UK is expected to emerge as a lucrative pocket in the Europe radiation-induced myelosuppression treatment market owing to the influx of medical tourists in the country, along with the availability of superior healthcare facilities.
Increasing adoption of technologically advanced medical equipment for the treatment of various chronic disorders such and cancer and kidney failure in the country is expected to augment the growth of the market in the forthcoming years.
Further, rising awareness regarding adjuvant treatment for cancer in the UK will continue boosting the market over the assessment period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Surging Incidence of Neutropenia to Drive Preference for Myelosuppression Treatment Regimen
Based on indication, sales in the neutropenia segment are projected to account for 43.3% of the total market share in 2022. Neutropenia is a condition where an individual deals with abnormally low counts of white blood cells.
Bone marrow malfunction caused by chemotherapy radiations is a chief factor driving sales in this segment. Lack of white blood cells in patients weakens the immune system and their ability to fight infections, which makes it imperative to seek treatment for the same.
Owing to the aforementioned factors, sales in this segment are projected to increase at a considerable pace over the assessment period.
Rising Awareness Regarding New Erythropoietin Stimulating Agents Will Bolster Sales
In terms of drug class, demand in the erythropoietin stimulating agents (ESA) segment is projected to remain high over the assessment period. ESAs effectively improve the efficacy of iron therapy in anemic patients after chemotherapy radiations, which is expected to continue pushing sales in the market.
Besides this, growing preference for intravenous iron therapy with a combination of ESAs is expected to complement the growth of the market in the forthcoming years. The combination of ESAs and IV iron therapy improve the red blood cells count as compared to other treatment using ESAs alone.
Sales of Myelosuppression Chemotherapy Drugs to Remain High Via Hospital Pharmacies
Based on the sales channel, sales in the hospital pharmacies segment are projected to increase at a considerable pace owing to the wide availability of therapeutic drugs in these shops. However, high convenience and timely delivery offered by online pharmacies will place them as a lucrative segment over the assessment period.
Oral Route of Administration for Myelosuppression Chemotherapy Medication to Gain Traction
In terms of route of administration, the oral route is expected to be preferred by both healthcare professionals and patients owing to ease of administration and high efficacy. Growing preference for non-invasive treatment options will also provide impetus to sales in this segment.
Leading players operating in the global radiation-induced myelosuppression treatment market are investing in research and development to improve lines of treatment for myelosuppression treatment. In addition to this, players are investing in mergers and acquisitions to strengthen their distribution channels.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Units for Volume and USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania, and MEA |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Russia, Poland, China, India, Thailand, Indonesia, Australia and New Zealand, Japan, GCC countries, North Africa, South Africa, others. |
| Key Market Segments Covered | Indication, Drug Class, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | Amgen Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd; Mylan N.V.; Pfizer Inc.; Janssen Global Services, LLC (Johnson & Johnson); Partner Therapeutics, Inc.; Mission Pharmacal Company; Myelo Therapeutics GmbH; Pluristem Therapeutics Inc. |
| Pricing | Available upon Request |
The global radiation-induced myelosuppression treatment market is expected to reach a valuation of USD 2.9 Billion in 2022.
The global Radiation-induced myelosuppression treatment market grew at a 3.4% CAGR between 2013 and 2021.
Increasing preference for non-invasive drug administration, along with the introduction of intravenous iron therapy are key trends driving radiation-induced myelosuppression treatment sales.
North America is projected to account for a dominant share of the global radiation-induced myelosuppression treatment market share during the forecast period.
The radiation-induced myelosuppression treatment market in Europe is anticipated to expand at a considerable pace over the assessment period.
1. Executive Summary 2. Market Introduction 3. Radiation Induced Myelosuppression Treatment Market Opportunity Analysis 4. Market Background 5. Macroeconomic Assumptions 6. Global Economic Outlook 7. Key Inclusions 8. Global Market Analysis 2013 to 2021 and Forecast 2022 to 2028 9. North America Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 10. Latin America Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 11. Western Europe Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 12. Eastern Europe Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 13. Asia Pacific excluding China (APEC) Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 14. Japan Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 15. MEA Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028 16. Forecast Factors: Relevance and Impact 17. Forecast Assumptions 18. Competition Analysis 18.1. Amgen Inc. 18.2. Novartis AG 18.3. Teva Pharmaceutical Industries Ltd 18.4. Mylan N.V. 18.5. Pfizer Inc. 18.6. Janssen Global Services, LLC (Johnson & Johnson) 18.7. Partner Therapeutics, Inc. 18.8. Mission Pharmacal Company 18.9. Myelo Therapeutics GmbH 18.10. Pluristem Therapeutics Inc. 19. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Region 19.1. North America 19.2. Latin America 19.3. Western Europe 19.4. Eastern Europe 19.5. Asia Pacific excluding Japan 19.6. Japan 19.7. Middle East and Africa 20. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Drug Class 20.1. Growth Factors 20.1.1. Granulocyte Colony-Stimulating Factor 20.1.2. Thrombopoietin Receptor Agonists 20.2. Erythropoietin-stimulating Agents 20.3. Thrombopoietic Agents 20.4. Iron supplementation 20.5. Others 21. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Route of Administration 21.1. Oral 21.2. Injectable 22. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Indication 22.1. Anemia 22.2. Neutropenia 22.3. Thrombocytopenia 23. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013 to 2021 and Forecast 2022 to 2028, By Distribution Channel 23.1. Hospital Pharmacies 23.2. Retail Pharmacies 23.3. Drug Stores 23.4. Online Pharmacies 24. Research Methodology
Explore Healthcare Insights
View Reports
Radiation-Induced Myelosuppression Treatment Market
